|
Study |
Phase |
Protocol |
Indication |
Status |
|
001 |
II |
Phase II Trial of Imatinib Mesylate (Gleevec) in Patients with Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial |
Soft tissue and bone sarcoma |
CLOSED |
|
002 |
III |
Phase III Randomized Trial of 120-minute infusion Gemcitabine v. 90-minute infusion Gemcitabine plus Docetaxel in unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society |
Unresectable soft tissue sarcoma |
CLOSED |
|
003 |
II |
SARC (Sarcoma Alliance for Research through Collaboration) Study: Phase II study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing's Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma |
Ewing's Sarcoma, Osteosarcoma and Chondrosarcoma |
Closed to accrual |
|
004 |
|
Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans |
Dermatofibrosarcoma protuberans |
Closed to accrual |
|
005 |
II |
Adjuvant treatment of high risk leiomyosarcoma with gemcitabine/docetaxel, followed by doxorubicin: a phase II multi-center trial |
Uterine leiomyosarcoma |
Closed to accrual |
|
006 |
II |
Phase II Trial of Neoadjuvant Chemotherapy in Sporadic Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors |
Sporadic and neurofibromatosis associated with Peripheral Nerve Sheath Tumors |
OPEN |
|
007 |
II |
A Phase II Trial of Perifosine in Patient with Chemo-Insensitive Sarcomas |
Chemo-insensitive sarcomas |
Closed to accrual |
|
009 |
II |
A Phase II Trial of Dasatinib in Advanced Sarcoma |
Advanced sarcoma |
OPEN |
|
010 |
II |
TBA |
GIST |
In
development |
|
011 |
II |
A Phase II Multi-Arm Trial of R1507 IGF1R, a Recombinant Human Monoclonal Antibody for the treatment of patients with recurrent or refractory Ewing's sarcoma, and other Soft Tissue Sarcomas |
Ewing's sarcoma, Osteosarcoma, synovial sarcoma, rhabdomyosarcoma and others |
Open (Only accruing Ewing's patients) |
|
012 |
II.5 |
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional,
Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor,
In Patients with Recurrent Osteosarcoma Localized to the Lung |
Osteosarcoma |
Open
|